Form 8-K - Current report:
SEC Accession No. 0001493152-25-004298
Filing Date
2025-01-30
Accepted
2025-01-30 17:20:14
Documents
23
Period of Report
2025-01-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 50868
2 ex4-1.htm EX-4.1 97422
3 ex4-2.htm EX-4.2 126125
4 ex4-3.htm EX-4.3 118920
5 ex10-1.htm EX-10.1 275711
6 ex10-2.htm EX-10.2 60456
7 ex99-1.htm EX-99.1 14899
8 ex99-2.htm EX-99.2 11760
9 ex99-1_001.jpg GRAPHIC 3094
10 ex99-2_001.jpg GRAPHIC 10549
  Complete submission text file 0001493152-25-004298.txt   1116619

Data Files

Seq Description Document Type Size
11 XBRL SCHEMA FILE pcsa-20250127.xsd EX-101.SCH 3060
12 XBRL LABEL FILE pcsa-20250127_lab.xml EX-101.LAB 34240
13 XBRL PRESENTATION FILE pcsa-20250127_pre.xml EX-101.PRE 22389
26 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3695
Mailing Address 7380 COCA COLA DRIVE SUITE 106 HANOVER MD 21076
Business Address 7380 COCA COLA DRIVE SUITE 106 HANOVER MD 21076 443-776-3133
Processa Pharmaceuticals, Inc. (Filer) CIK: 0001533743 (see all company filings)

EIN.: 451539785 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39531 | Film No.: 25574936
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)